These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 28947112

  • 21. Tetrabenazine treatment in movement disorders.
    Paleacu D, Giladi N, Moore O, Stern A, Honigman S, Badarny S.
    Clin Neuropharmacol; 2004; 27(5):230-3. PubMed ID: 15602104
    [Abstract] [Full Text] [Related]

  • 22. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.
    Jankovic J.
    Ann Neurol; 1982 Jan; 11(1):41-7. PubMed ID: 6460467
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
    Curtis K, Sung V.
    J Clin Pharmacol; 2024 Feb; 64(2):178-181. PubMed ID: 37565322
    [Abstract] [Full Text] [Related]

  • 26. An evidence-based approach in the treatment of Huntington's disease.
    Mestre TA, Ferreira JJ.
    Parkinsonism Relat Disord; 2012 May; 18(4):316-20. PubMed ID: 22177624
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The long-term effect of tetrabenazine in the management of Huntington disease.
    Fasano A, Cadeddu F, Guidubaldi A, Piano C, Soleti F, Zinzi P, Bentivoglio AR.
    Clin Neuropharmacol; 2008 May; 31(6):313-8. PubMed ID: 19050408
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A systematic review of the treatment studies in Huntington's disease since 1990.
    Bonelli RM, Hofmann P.
    Expert Opin Pharmacother; 2007 Feb; 8(2):141-53. PubMed ID: 17257085
    [Abstract] [Full Text] [Related]

  • 33. Preclinical motor manifestations of Huntington disease.
    McGarry A, Biglan KM.
    Handb Clin Neurol; 2017 Feb; 144():93-98. PubMed ID: 28947128
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Tetrabenazine in the treatment of Huntington's chorea.
    Huang CY, McLeod JG, Holland RT, Elliot C.
    Med J Aust; 1976 Apr 17; 1(16):583-4. PubMed ID: 132600
    [Abstract] [Full Text] [Related]

  • 36. The emerging role of clozapine in the treatment of movement disorders.
    Factor SA, Friedman JH.
    Mov Disord; 1997 Jul 17; 12(4):483-96. PubMed ID: 9251065
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Zotepine in Huntington's disease.
    Bonelli RM, Niederwieser G, Lahousen T, Hofmann P.
    Hum Psychopharmacol; 2003 Apr 17; 18(3):227-9. PubMed ID: 12672176
    [Abstract] [Full Text] [Related]

  • 39. Alpha methylparatyrosine and tetrabenazine in movement disorders.
    Lang AE, Marsden CD.
    Clin Neuropharmacol; 1982 Dec 17; 5(4):375-87. PubMed ID: 6130839
    [Abstract] [Full Text] [Related]

  • 40. Tetrabenazine for involuntary movement disorders.
    Kingston D.
    Med J Aust; 1979 Jun 30; 1(13):628-30. PubMed ID: 158700
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.